Zestril ( DrugBank: - )

3 diseases

ID	Disease name (Link within this page)	Number of trials
19	Lysosomal storage disease	1
67	Polycystic kidney disease	1
222	Primary nephrotic syndrome	2

19. Lysosomal storage disease

Clinical trials : 899 / Drugs : 684 - (DrugBank : 99) / Drug target genes : 51 - Drug target pathways : 182

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2007-007482-21-GB (EUCTR)	09/11/2009	17/08/2009	Multi-center, Open-label Study of the Safety and Efficacy of Control of Proteinuria with ACE Inhibitors and ARBS in Patients with Fabry Diseaswe Who Are receiving Farazyme : Tha Farazyme + Arbs + ACE inhibitors Treatments (FAACET) Study: The FAACET Study - The FAACET Study	Multi-center, Open-label Study of the Safety and Efficacy of Control of Proteinuria with ACE Inhibitors and ARBS in Patients with Fabry Diseaswe Who Are receiving Farazyme : Tha Farazyme + Arbs + ACE inhibitors Treatments (FAACET) Study: The FAACET Study - The FAACET Study	Fabry disease with proteinuria. MedDRA version: 9.1;Level: LLT;Classification code 10018058;Term: Gene genetic abnormality MedDRA version: 9.1;Classification code 10037032;Term: Proteinuria	Trade Name: perdix Product Name: perdix Trade Name: Zestoretic 10,20 Product Name: ZESTORIC Trade Name: INNOZIDE Product Name: innozide Trade Name: lisinopril Product Name: lisinopril Trade Name: zestril Product Name: zestril Trade Name: coversyl Product Name: coversyl Trade Name: coversyl PLUS Product Name: coversyl PLUS Trade Name: Accupro Product Name: Accupro Trade Name: Accuretic Product Name: Accuretic Trade Name: lopace Product Name: lopace Trade Name: lopace Product Name: lopace Trade Name: triapin Product Name: triapin& triapin Mite	Salford Royal NHS Foundation Trust	NULL	Not Recruiting			Female: yes Male: yes		Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes	United Kingdom

67. Polycystic kidney disease

Clinical trials : 221 / Drugs : 212 - (DrugBank : 55) / Drug target genes : 40 - Drug target pathways : 151

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2005-003182-16-GB (EUCTR)	26/08/2005	29/07/2005	Blood Pressure Optimisation In Patients With Polycystic Kidney Disease And Hypertension By Rotation Through The Main Therapeutic Classes Of Antihypertensive Drugs.	Blood Pressure Optimisation In Patients With Polycystic Kidney Disease And Hypertension By Rotation Through The Main Therapeutic Classes Of Antihypertensive Drugs.	Polycystic kidney disease	Trade Name: CARDURA Product Name: DOXAZOSIN Trade Name: MONOCOR Product Name: BISOPROLOL Trade Name: ZESTRIL Product Name: LISINOPRIL Trade Name: ISTIN Product Name: AMLODIPINE Trade Name: AMIAS Product Name: CANDESARTAN Trade Name: APRINOX Product Name: BENDROFLUMETHIAZIDE	Addenbrooke's Hospital Trust	NULL	Not Recruiting			Female: yes Male: yes	42	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes	United Kingdom

222. Primary nephrotic syndrome

Clinical trials : 310 / Drugs : 295 - (DrugBank : 117) / Drug target genes : 63 - Drug target pathways : 194

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2005-004460-22-BE (EUCTR)	12/05/2006	05/12/2005	Multicenter, pilot, open, randomized, parallel group study to evaluate the association of Neoral with ACE-inhibitors as compared to corticosteroids with ACE-inhibitors in the treatment of de novo nephrotic syndrome due to focal segmental glomerulosclerosis.	Multicenter, pilot, open, randomized, parallel group study to evaluate the association of Neoral with ACE-inhibitors as compared to corticosteroids with ACE-inhibitors in the treatment of de novo nephrotic syndrome due to focal segmental glomerulosclerosis.	focal and segmental glomerulosclerosis	Trade Name: Neoral Product Name: Neoral Trade Name: Medrol Product Name: Medrol Trade Name: zestril Product Name: zestril	Hopital Erasme	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	50		Belgium
2	EUCTR2005-004469-40-BE (EUCTR)	12/05/2006	05/12/2005	Multicenter, pilot, open, randomized, parallel group study to evaluate the association of Neoral with ACE-inhibitors as compared to ACE-inhibitors alone in the treatment of de novo nephrotic syndrome due to idiopathic membranous glomerulopathy	Multicenter, pilot, open, randomized, parallel group study to evaluate the association of Neoral with ACE-inhibitors as compared to ACE-inhibitors alone in the treatment of de novo nephrotic syndrome due to idiopathic membranous glomerulopathy	Membranous Nephropathy	Trade Name: Neoral Product Name: Neoral Trade Name: zestril Product Name: zestril	Hopital Erasme	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	50		Belgium